CanSino Biologics Inc. announced that, the phase III clinical trial for the Absorbed Tetanus Vaccine developed by the Company, was officially initiated recently and the first trial patient case has been formally enrolled. Phase III clinical trial will evaluate the safety and immunogenicity of Absorbed Tetanus Vaccines in population aged above 18 years old, and conduct a randomized, blinded, positive control clinical trial. The Absorbed Tetanus VaccINE is fermented with animal-free culture medium and safer, and the stable industrial scale processes have been identified.

This vaccine is mainly used for non-neonatal tetanus prevention, which will further enrich the Company's product pipeline and enhance its core competitiveness. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.